Good morning. Elizabeth Cooney here, minding the Pharmalittle store today. Ed will be back tomorrow, but here’s what’s brewing today.

After weeks of anticipation, Jacobus Pharmaceutical has priced its rare disease drug at $80 a tablet, or less than half the price of a similar pill sold by its upstart rival, Catalyst Pharmaceuticals (CPRX), STAT informs us. The move is likely to set up a closely watched battle between a small, family-run drug maker that used to supply the drug for free and a newcomer that secured seven years’ patent protection before Jacobus won FDA approval for a pediatric version.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy